EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Greg Durm, Hirva Mamdani, Sandra Althouse, Susan Perkins, Salma K Jabbour, Apar Kishor Ganti, Shadia Jalal, Jason Chesney, Jarushka Naidoo, Borys Hrinczenko, Mary Jo Fidler, Ticiana A Leal und 3 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010316 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Greg Durm und 14 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA gdurm@iu.edu. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Non-Small-Cell Lung, Ipilimumab, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown. Despite improved outcomes with 12 months of durvalumab, which has become the standard of care, new strategies to improve survival are needed. This study evaluates dual immunotherapy in the consolidation setting following concurrent chemoradiation as well as a shorter (6 months) treatment duration.

Methods

Following concurrent chemoradiation, subjects were randomized 1:1 to nivolumab alone (480 mg intravenously every 4 weeks) or combination nivolumab (240 mg intravenously every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) for up to 6 months. Primary endpoint was 18-month progression-free survival (PFS), and each arm was compared with appropriate historical controls. Secondary endpoints included overall survival (OS), time to metastatic disease, and toxicity.

Results

105 patients enrolled (54 nivolumab alone; 51 nivolumab/ipilimumab). Median follow-up was 29.1 months for nivolumab and 30 months for nivolumab/ipilimumab. For nivolumab alone, 18-month PFS was 65.5% (95% CI, 49.8% to 77.3%), a statistically significant improvement over the historical control of chemoradiation alone (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Non-Small-Cell LungIpilimumabLung NeoplasmsChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansMaleFemaleMiddle AgedAgedNeoplasm StagingAdultAged, 80 and over

Stichwörter der Autor:innen

IpilimumabLung CancerNivolumabPneumonitis

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA gdurm@iu.edu.
  • Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Indiana University Richard M Fairbanks Department of Biostatistics, Indianapolis, Indiana, USA.
  • Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Oncology-Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • VA Nebraska-Western Iowa Health Care System, Grand Island, Nebraska, USA.

Förderung

  • NCI NIH HHS
  • Bristol Myers Squibb

Zitieren

APA

Durm, G., Mamdani, H., Althouse, S., Perkins, S., Jabbour, S. K., Ganti, A. K., Jalal, S., Chesney, J., Naidoo, J., Hrinczenko, B., Fidler, M. J., Leal, T. A., Feldman, L., Fujioka, N., & Hanna, N. H. (2025). Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010316

Vancouver

Durm G, Mamdani H, Althouse S, Perkins S, Jabbour SK, Ganti AK, et al. Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010316

BibTeX
@article{Durm2025,
  author = {Durm, Greg and Mamdani, Hirva and Althouse, Sandra and Perkins, Susan and Jabbour, Salma K and Ganti, Apar Kishor and Jalal, Shadia and Chesney, Jason and Naidoo, Jarushka and Hrinczenko, Borys and Fidler, Mary Jo and Leal, Ticiana A and Feldman, Lawrence and Fujioka, Naomi and Hanna, Nasser H},
  title = {Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010316}
}
Kostenlos starten →